Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

May 21, 2024

BUY
$2.33 - $5.07 $3,746 - $8,152
1,608 Added 95.94%
3,284 $7,000
Q3 2023

Oct 30, 2023

BUY
$2.33 - $5.07 $3,746 - $8,152
1,608 Added 95.94%
3,284 $8,000
Q2 2023

May 21, 2024

SELL
$4.67 - $6.55 $56 - $78
-12 Reduced 0.71%
1,676 $8,000
Q2 2023

Jul 27, 2023

SELL
$4.67 - $6.55 $56 - $78
-12 Reduced 0.71%
1,676 $8,000
Q1 2023

May 21, 2024

BUY
$4.95 - $6.09 $2,093 - $2,576
423 Added 33.44%
1,688 $9,000
Q1 2023

Apr 27, 2023

BUY
$4.95 - $6.09 $2,093 - $2,576
423 Added 33.44%
1,688 $10,000
Q4 2022

May 21, 2024

BUY
$5.09 - $9.05 $6,438 - $11,448
1,265 New
1,265 $7,000
Q4 2022

Jan 31, 2023

BUY
$5.09 - $9.05 $524 - $932
103 Added 8.86%
1,265 $7,000
Q3 2022

Oct 21, 2022

BUY
$3.5 - $7.2 $4,067 - $8,366
1,162 New
1,162 $7,000

Others Institutions Holding MCRB

About Seres Therapeutics, Inc.


  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $114M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.